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Selective inhibition of inducible nitric oxide inhibition enhances inflammation, NO may be involved as a central mediator
intraglomerular coagulation in chronic anti-Thy 1 nephritis. of glomerular damage [2–4]. NO is generated from the
Background. A particular Lewis rat substrain (LEW/Maa) substrate l-arginine by NO synthases (NOSs). Threedevelops chronic glomerulonephritis in the anti-Thy 1 model
different NOS isoforms were described: Transcriptional(aThy 1-GN) characterized by increased microaneurysm forma-
activation of inducible NO synthase (iNOS) by inflam-tion, chronic glomerular sclerosis and persistent albuminuria.
This phenotype is accompanied by increased and prolonged matory cytokines [such as, interferon-gamma (IFN-),
glomerular induction of inducible nitric oxide synthase (iNOS) interleukin-1beta (IL-1), tumor necrosis factor-alpha
when compared to the LEW/Moe substrain, in which aThy (TNF-)] leads to a calcium-independent release of po-1-GN resolves quickly. We investigated the effect of selective
tentially large amounts of NO representing an importantiNOS inhibition by l-N6-(1-iminoethyl)-lysine (L-NIL) admin-
cytotoxic effector mechanism in host defense as well asistration on aThy 1-GN in LEW/Maa rats.
Methods. Nephritic rats were studied over a period of 7 in autoimmune diseases [5]. The calcium-dependent and
days. L-NIL–treated animals received 20 mg/day L-NIL in the constitutively expressed NOSs can be divided into an
drinking water starting two days prior to disease induction.
endothelial (eNOS) and a neuronal (nNOS) isoform.iNOS activity was determined in cultured glomeruli and in
NO release by these isoforms has a pulsatile and short-urine samples, respectively. Severity of aThy 1-GN was deter-
mined by scoring glomerular matrix expansion and microaneur- lived character. Neuronal NOS-dependent NO release
ysm formation, and by albuminuria measurements (ELISA). serves as a neurotransmitter, while eNOS-dependent NO
Immunohistochemical evaluation was performed including release regulates vascular tone by promoting cyclic 35-
staining for macrophages (ED-1), platelets (PL-1) and fibrin
guanosine monophosphate (cGMP)-dependent vasculardeposition.
smooth muscle cell (VSMC) relaxation and inhibitsResults. L-NIL treated rats (NIL) showed a significant de-
crease in peak nitrate production by ex vivo cultured glomeruli, platelet aggregation [6, 7].
and in urinary nitrate excretion versus untreated nephritic rats Cook and co-workers were the first to demonstrate
(NIL). Mean arterial pressure remained unchanged in both an induction of iNOS during experimental accelerated
NIL and NIL rats. NIL rats developed significantly in-
nephrotoxic nephritis in the rat [2]. Peak NO-synthesiscreased albuminuria (44%) associated with a significant in-
and severity of inflammation in this model were associatedcrease in glomerular platelet (45%) and fibrin deposition
(48%). with infiltrating macrophages and could be abrogated by
Conclusions. Selective inhibition of iNOS aggravated albu- macrophage depletion due to whole body irradiation [8].
minuria in chronic aThy 1-GN in LEW/Maa rats. Induction of This led to the hypothesis that bone marrow-derived mac-iNOS during the inflammatory phase of this model may be a
rophages represent the major source of glomerular iNOSpartially protective mechanism by interfering with intraglomer-
ular coagulation processes. in experimental glomerulonephritis (GN). Several mod-
els of experimental GNs used competitive NOS antago-
nists to investigate the pathophysiological role of glomer-
The pathogenetic mechanisms leading from initial glo- ular iNOS up-regulation and they generated seemingly
merular damage to end-stage renal failure are incom- conflicting results. Administration of NG-monomethyl-l-
pletely understood [1]. Since up-regulation of nitric oxide arginine (L-NMMA), an unselective NOS inhibitor, pre-
(NO) synthesis can be detected at sites of glomerular vented the development of lupus nephritis in MRL-1pr/
1pr mice and suppressed mesangial cell lysis and protein-
uria in anti-Thy 1-GN (aThy 1-GN) [9, 10]. In contrast,Key words: platelets, L-NIL, glomerulonephritis, fibrin, mesangioproli-
ferative glomerulonephritis, renoprotection. rats with heterologous nephrotoxic nephritis developed
increased proteinuria when treated with unselective NOS 2002 by the International Society of Nephrology
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blockade [11]. Selective iNOS blockade using l-N6- Camon, Wiesbaden, Germany) to stain infiltrating macro-
phages, a murine monoclonal IgG antibody to detect in-(1-iminoethyl)-lysine (L-NIL) had no effect on early glo-
merular injury and leukocyte infiltration in the same traglomerular platelets (kindly provided by W. Tiemens,
Groningen, Netherlands) and a polyclonal rabbit IgG anti-model [12].
We recently discovered a particular inbred Lewis rat body to fibrinogen (DAKO, Glostrup, Denmark). Tissue
sections were incubated sequentially with biotinylatedsubstrain (LEW/Maa) that develops chronic aThy 1-GN
with increased microaneurysm formation and persistent horse-anti-mouse (Vector Labs, Burlingame, CA; USA) or
goat-anti-rabbit antibody (Vector Labs). The ABC-Elitealbuminuria for more than six months. This observation
stood in clear contrast to another Lewis rat substrain reagent (Vector Labs) and 3,3-diaminobenzidine (DAB;
nickel chloride enhancement) were used as chromogens.(LEW/Moe), which showed rapid and complete healing
of glomerular lesions after less than one month in the Sections were counterstained with methyl green. Fifty
to 70 consecutive glomerular cross-sections were countedsame model. One major difference between the two sub-
strains was a significant up-regulation of glomerular to quantitate intraglomerular macrophage infiltration,
and mean values per kidney were calculated. Quantita-iNOS expression and activity in the LEW/Maa rats. Our
current study examines the influence of continuous ad- tion of immunostaining for platelets and fibrin deposition
was performed by grid-counting. For this purpose, a gridministration of L-NIL, which is currently the best avail-
able selective iNOS inhibitor for in vivo use, on the composed of 100 dots was superimposed on 30 to 50
consecutive glomeruli, the percentage of dots overlyingdisease course of chronic aThy 1-GN in this Lewis rat
substrain [12–14]. stained areas was counted and results were expressed as
mean values for each kidney.
METHODS Albuminuria measurements
Animal model and study design Rat albuminuria was determined by using a modified
All animal experiments were approved by the local competitive enzyme-linked immunosorbent assay tech-
review boards. LEW/Maa rats were provided by Frans nique [18] with a peroxidase-conjugated anti-rat albumin
Weekers from the University of Limburg (Maastricht, antibody (ICN-Biomedical, Eschwege, Germany). Mea-
The Netherlands). Anti-Thy 1 glomerulonephritis was surements of 24-hour urine samples were performed in
induced by single intravenous bolus injection of mono- duplicates of four different urine dilutions (1:50; 1:500;
clonal antibodies [ER4-hybridoma; 1 mg/kg body weight 1:5000; 1:20,000) of each animal.
(BW); N  6 rats per group] [15]. Control rats were
Nitrate and nitrite measurements ininjected with phosphate-buffered saline (PBS). iNOS in-
culture supernatantshibition was achieved by administration of 60 mg/kg BW
L-NIL per day in the drinking water. Treatment was Isolated glomeruli were cultured at a concentration of
3000/mL in phenol-red-free Dulbecco’s modified Eagle’sstarted two days prior to disease induction and continued
until day 6. Animals were sacrificed under ether anesthe- medium (DMEM) supplemented with penicillin/strepto-
mycin, l-glutamine, tetrahydrobiopterin and 0.5% fetalsia on day 1 (1d), day 3 (3d) and day 7 (7d), respectively.
Kidneys were perfused with 25 mL ice-cold PBS, re- bovine serum (FBS). After 48 hours, supernatants were
collected and centrifuged at 4000 rpm to remove glomer-moved and small cortex pieces were fixed in methyl Car-
noy’s solution for immunohistochemistry and histologi- uli. Samples were treated with nitrate reductase (from
Aspergillus species, 0.1 U/100 L; Boehringer Mann-cal evaluation, respectively. Glomeruli were isolated
from the remainder of the kidneys by graded sieving heim, Mannheim, Germany) in the presence of NADPH
prior to nitrite measurements using the Griess assay astechnique as previously described [16].
previously described [16]. Colorimetric reaction was de-
Renal morphology termined using an automated plate reader (DYNA-
Methyl Carnoy’s-fixed kidney tissue sections were em- TECH, Denkendorf, Germany) reading extinction at 550
bedded in paraffin and stained with periodic acid-Schiff nm and compared to a standard curve of sodium nitrate.
(PAS). Glomerular matrix expansion was scored in a
Blood pressureblinded fashion by two investigators as previously pub-
lished (matrix score of 1  normal glomerular morphol- Measurements were performed using the tail cuff-
method [programmed sphygmomanometer, BP-98A (Sof-ogy to 4 diffuse and complete glomerulosclerosis) [16].
Formation of microaneurysms served as an indicator of tron, Tokyo, Japan)] [19].
severe mesangiolysis.
Statistical analysis
Immunoperoxidase staining Data are presented as means 	 standard deviation
(SD) unless otherwise noted. Statistical significance (de-Four-micrometer sections of methyl Carnoy’s fixed kid-
ney tissues were processed as described previously [17]. fined as P 
 0.05) was evaluated with the Student t test,
Mann-Whitney U test or paired t test where appropriate.We used a murine monoclonal IgG antibody (clone ED-1;
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Fig. 1. A significant rise in urinary nitrite/nitrate (NO2/NO3) excretion
was observed in untreated animals ( ) 3 days and 7 days after disease
induction. The urinary NO2/NO3 excretion was completely prevented
by the administration of l-N6-(1-iminoethyl)-lysine (L-NIL; ). L-NIL
treatment did not affect the urinary NO2 /NO3-excretion in non-nephritic Fig. 2. Following anti-Thy 1 glomerulonephritis (aThy 1-GN) induc-
rats. N  6, data represent means 	 SD, *P 
 0.05 comparing NIL tion, a tremendous increase in albuminuria developed in both NIL
vs. NIL rats. () and NIL ( ) rats, which reached its maximum after 7 days. NIL
treatment led to a significant increase in albuminuria on day 7 compared
to NIL animals. Albuminuria in non-nephritic controls: NIL 0.15 	
0.03 vs.NIL 0.22	 0.07; N 6 rats per time point, data are expressed
as means 	 SD, *P 
 0,05 comparing NIL vs. NIL rats.Table 1. Effects of l-N6-(1-iminoethyl)-lysine (NIL) for anti-Thy 1
glomerulonephritis (aThy 1-GN)
Group NIL NIL
Mean arterial blood pressure differences in glomerular matrix expansion or microan-
mm Hg 97	7 92	5
eurysm formation, the latter indicating a similar degreeGlomerular matrix score
range: 1–4 3.4	0.07 3.36	0.13 of mesangiolysis in both substrains (Table 1). However,
Glomerular microaneurysms PAS staining revealed that glomeruli and especially the
prevalence in % 15.8	7.1 11.4	6.1
microaneurysms were filled with significantly more pro-
Systemic blood pressure was measured five days after disease induction. Semi- teinaceous material in the NIL animals. This promi-quantitative matrix score and microaneurysms were obtained seven days after
disease induction. Data are means	SD. All differences were not significant. nent PAS-positive material could be identified as fibrin
by immunoperoxidase staining. Subsequent quantitative
analysis by grid counting revealed significantly increased
glomerular fibrin deposition in NIL treated animals
RESULTS versus NIL animals on day 7 after disease induction
L-NIL treatment (NIL) led to complete normaliza- (Fig. 3).
tion of the increased urinary nitrite/nitrate excretion ob- Since NO inhibition potentially enhances platelet ag-
served in the non-treated nephritic animals (NIL) on gregation, increased fibrin deposition may have been a
days 3 and 7 after disease induction (Fig. 1). Basal urinary consequence of glomerular thrombosis. We therefore
nitrite/nitrate excretion in non-nephritic animals re- performed immunoperoxidase stainings for platelets.
mained unchanged by L-NIL treatment. There was a significant increase in positively stained glo-
To assess whether iNOS inhibition was selective and merular areas in NIL animals on day 1 and a similar
did not affect endothelium-dependent NO release, blood trend on day 7 in the NIL rats (Fig. 3). No differences
pressure measurements were performed using the tail between NIL and NIL groups regarding the influx
cuff-method in non-anesthetized animals on day 5 after of monocytes/macrophages as determined by immuno-
disease induction. As shown in Table 1, both nephritic staining for ED-1 (data not shown) were found.
NIL andNIL animals remained normotensive. There
also was no influence of L-NIL treatment on the rate of
DISCUSSIONbody weight gain or on water intake (data not shown).
As shown in Figure 2, maximal albuminuria on day 7 The aim of our study was to determine the effect
of continuous selective iNOS inhibition on the diseasewas significantly elevated in NIL animals when com-
pared to NIL rats. Histological evaluation of PAS- course of chronic aThy 1-GN in LEW/Maa rats. We have
previously shown that chronic aThy 1-GN in LEW/Maastained kidney sections demonstrated no quantitative
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nase infusion as a tool to study the glomerular l-argi-
nine/NO system, we found increased glomerular throm-
bosis and subsequent fibrin deposition in association with
increased proteinuria as a consequence of continuous
selective iNOS inhibition [20]. Thus, it seems likely that
the effect of arginase infusion had also been due to sub-
strate limitation for iNOS-dependent NO release.
Our study indicates that iNOS-dependent intraglo-
merular NO release may serve as a central antithrom-
botic agent via its inhibitory effects on platelet adhesion
during experimental nephritis [21]. The involvement of
platelet aggregation in this model has been previously
described by Poelstra et al [22, 23]. Inhibition of platelet
Fig. 3. Immunoperoxidase stainings were analyzed by superimposing aggregation by prostacyclin and specific adenine nucleo-
a grid on 30 to 50 glomerular cross sections in order to calculate the tides had beneficial effects on glomerular damage andpercentage of positively stained glomerular area. N  6; data represent
proteinuria in aThy 1-GN. In this context, aggravatedmeans  SD, *P 
 0.05 comparing NIL () vs. NIL ( ) rats. (A)
Immunostaining for platelets (PL-1) revealed a significant increase in proteinuria due to selective iNOS blockade may be medi-
positively stained glomerular area one day after disease induction. (B) ated by interactions between an increased release ofGlomerular fibrin deposition was significantly enhanced by NIL-treat-
highly charged platelet factor 4 and the glomerular base-ment seven days after disease induction.
ment membrane [1], or by platelet activation and subse-
quent local release of potentially harmful growth factors
[such as, platelet-derived growth factor (PDGF), trans-
rats is characterized by a remarkable up-regulation of forming growth factor beta (TGF-), basic fibroblast
glomerular iNOS expression and activity within the first growth factor (bFGF), etc.] [24].
week after disease induction when compared to a fast- It was previously shown that kidneys acquire a hypo-
healing Lewis rat substrain. fibrinolytic and procoagulant state during development
The major, although unexpected, observation of the of experimental glomerulonephritis that is characterized
present study was that selective inhibition of iNOS by by up-regulation of plasminogen activator inhibitor-1
L-NIL aggravated the disease course of aThy 1-GN in (PAI-1) and tissue factor (TF) [25–30]. Studies have dem-
LEW/Maa rats in terms of significantly increased albu- onstrated the suppression of PAI-1 release and mRNA
minuria. These results, however, are in line with some expression by NO mainly generated via the eNOS/cGMP-
former studies. Waddington et al reported increased pro- mediated pathway [27, 28]. iNOS-dependent NO genera-
teinuria and glomerular thrombosis in nephrotoxic ne- tion in glomerular inflammation may have similar effects
phritis by arginase infusion, which greatly but unspecif- on local PAI-1 release. Therefore, enhanced glomerular
ically reduced NO synthesis by substrate depletion [20]. coagulation mediated in part by PAI-1 up-regulation due
Ferrario et al reported an exacerbated disease course in to iNOS inhibition cannot be ruled out in our model.
the same model following the administration of the un- Interactions between NO and TF have also been recently
selective NOS inhibitor L-NAME, however, the increased described by Adam and colleagues [29]. They were the
glomerular damage may have been caused by systemic first to demonstrate that modification of TF by peroxyni-
hypertension in this experiment [11]. In contrast, unse- trite, a product of high-output NO and superoxide re-
lective NOS inhibition by single-bolus L-NMMA injec- lease, significantly reduced its procoagulant activity in
tion directly prior to aThy 1-GN induction was previously vitro [29]. L-NIL treatment thus may have abrogated
reported to cause reduced mesangiolysis and proteinuria the protective anticoagulant function of iNOS-induced
in aThy 1-GN [10]. nitrotyrosine modification of TF, thereby provoking un-
In our present study, unselective systemic eNOS inhi- wanted intraglomerular procoagulant activity [29, 30].
bition by L-NIL treatment could be ruled out as a poten- Our results represent the sum of the effects of continu-
tial influence on the disease course, since mean arterial ous selective iNOS inhibition for six days in aThy 1-GN.
blood pressure remained unchanged and was normoten- These data do not entirely exclude cytotoxic effects of
sive in bothNIL andNIL animals. Since the selectiv- iNOS-dependent NO release and potentially beneficial
ity of L-NIL is comparably high versus nNOS and eNOS, effects of iNOS blockade when limited especially to the
effective renal nNOS inhibition also seems unlikely in initiation phase of this model. The previous results of
this study [13]. Our measurements of glomerular nitrate Narita et al are suggestive that single-bolus NOS inhibi-
production and urinary nitrate excretion are further tion in the induction phase of aThy 1-GN may result in
proof that iNOS inhibition was highly effective in vivo. significant protection from glomerular damage, although
this study could not define whether these beneficial ef-Similar to the results of Waddington et al using argi-
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selective inhibition in neutrophil-dependent glomerulonephritis.fects were due to iNOS inhibition or due to inhibition
Clin Exp Immunol 118:309–314, 1999
of one of the constitutive NOS isoforms [10]. 13. Boer R, Ulrich WR, Klein T, et al: The inhibitory potency and
selectivity of arginine substrate site nitric-oxide synthase inhibitorsIn summary, our results demonstrate that iNOS is clearly
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zymes. Mol Pharmacol 58:1026–1034, 2000
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17. Burg M, Ostendorf T, Mooney A, et al: Treatment of experimen-and Raij [31]. The timing of selective or unselective NOS
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